Fig. 1: Study cohorts and workflow.
From: Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity
A schematic depiction illustrating the study cohorts and workflow. The study comprised two primary cohorts, discovery and replication cohorts, both of which consisted of patients who received anti-TB medications. In the discovery cohort, sequencing was conducted for a comprehensive set of 380 pharmacogenes. Subsequently, the replication cohort was genotyped specifically for the NAT2 and ATP7B genes. Furthermore, we included a Korean population control group, which was sourced from the Korean Genome Project dataset, encompassing genetic data for 1048 healthy individuals who had undergone genome sequencing.
